Golimumab (Simponi)

Indications

Moderate-to-severely active UC in adults

Contraindications

Moderate or severe heart failure; severe active infection. Caution in malignancy; demyelinating disorders; mild heart failure; predisposition to infection; hepatic impairment; risk factors for dysplasia or carcinoma of the colon. Evaluate for tuberculosis before treatment. Use only if essential in pregnancy. Avoid breastfeeding during treatment and for 6 months afterwards. | Potential side effects: Associated with infections, including tuberculosis, septicaemia, and hepatitis B reactivation. Common: abscess; alopecia; anaemia; asthma; bone fracture; chest discomfort; depression; dizziness; fever; headache; high blood pressure; insomnia; nausea; respiratory and gastrointestinal disorders; skin reactions; mouth ulcers

Preparations Available

Subcutaneous injection

Quantity

Dose: Initially 200mg, then 100mg after 2 weeks and 50–100mg maintenance every 4 weeks. Review if no response after 4 doses.

Sizes Available

100mg/1ml solution, £1525.94; 50mg/0.5ml solution, £762.97

Price

100mg/1ml solution, £1525.94; 50mg/0.5ml solution, £762.97

More on: Biologics